These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16510049)

  • 1. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.
    Bays H; Dujovne CA
    Curr Atheroscler Rep; 2006 Mar; 8(2):144-56. PubMed ID: 16510049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk.
    Bays H; Rodbard HW; Schorr AB; González-Campoy JM
    Curr Treat Options Cardiovasc Med; 2007 Aug; 9(4):259-71. PubMed ID: 17761111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular risks and management of obesity in children and adolescents.
    Jolliffe CJ; Janssen I
    Vasc Health Risk Manag; 2006; 2(2):171-87. PubMed ID: 17319462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of weight reduction therapy on obstructive sleep apnea syndrome and arterial stiffness in patients with obesity and metabolic syndrome.
    Iguchi A; Yamakage H; Tochiya M; Muranaka K; Sasaki Y; Kono S; Shimatsu A; Satoh-Asahara N
    J Atheroscler Thromb; 2013; 20(11):807-20. PubMed ID: 23883546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of diabetes development in those with the metabolic syndrome.
    Tupper T; Gopalakrishnan G
    Med Clin North Am; 2007 Nov; 91(6):1091-105, viii-ix. PubMed ID: 17964911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the metabolic syndrome: the impact of lifestyle modification.
    Pritchett AM; Foreyt JP; Mann DL
    Curr Atheroscler Rep; 2005 Mar; 7(2):95-102. PubMed ID: 15727723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything.
    Bays H
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):393-404. PubMed ID: 15889967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiposopathy is "sick fat" a cardiovascular disease?
    Bays HE
    J Am Coll Cardiol; 2011 Jun; 57(25):2461-73. PubMed ID: 21679848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.
    Maksimov ML; Svistunov AA; Tarasov VV; Chubarev VN; Ávila-Rodriguez M; Barreto GE; Dralova OV; Aliev G
    Curr Pharm Des; 2016; 22(7):895-903. PubMed ID: 26648466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
    Bays H; Abate N; Chandalia M
    Future Cardiol; 2005 Jan; 1(1):39-59. PubMed ID: 19804060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox.
    Bays H
    Curr Atheroscler Rep; 2014 May; 16(5):409. PubMed ID: 24659222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Diet in Patients with Metabolic Syndrome.
    Almeda-Valdes P; Herrera-Mercadillo RJ; Aguilar-Salinas CA; Uribe M; Méndez-Sánchez N
    Curr Med Chem; 2019; 26(19):3613-3619. PubMed ID: 28521684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.